ezatiostat
Small molecule targets GSTP1 via inhibition
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01062152 | Nov 2009 → Nov 2012 | myelodysplastic syndrome | Telik | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00280631 | Feb 2006 → Mar 2008 | myelodysplastic syndrome | Telik | Completed | No outcome recorded |
| Phase 1/2 | NCT00035867 | Apr 2002 → May 2007 | myelodysplastic syndrome | Telik | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01422486 | Oct 2011 → Feb 2013 | myelodysplastic syndrome associated with isolated del(5q) | Telik | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01459159 | Oct 2011 → Feb 2013 | myelodysplastic syndrome | Telik | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00909584 | Apr 2009 → May 2013 | severe congenital neutropenia | Telik | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00701870 | Oct → Nov 2008 | non-small cell lung carcinoma | Telik | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00700206 | May 2008 → Jul 2011 | myelodysplastic syndrome | Telik | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ezatiostat | “Phase 1 patients received ezatiostat at 5 dose levels (50, 100, 200, 400 and 600 mg/m2)” PMID 19439093 ↗ May 2009 |
| Known as | Ezatiostat hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110585 ↗ |
| Known as | Ezatiostat Hydrochloride | “Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to...” NCT01062152 ↗3“Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)” NCT00700206 ↗ “Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia” NCT00909584 ↗ “ezatiostat hydrochloride (Telintra®)” NCT00701870 ↗ |
| Known as | Ezatiostat Hydrochlorine | “Drug: Ezatiostat Hydrochlorine” NCT00280631 ↗ |
| Known as | Telintra | “Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to...” NCT01062152 ↗3“Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug” PMID 19439093 ↗ May 2009 “Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome” NCT01459159 ↗ “ezatiostat hydrochloride (Telintra®)” NCT00701870 ↗ |
| Known as | TER-199 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110585 ↗ |
| Known as | TLK-199 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110585 ↗ |
| Known as | TLK199 | “Phase 1 Dose-Ranging Study of Ezatiostat Hydrochloride (Telintra®, TLK199 Tablets)in Combination With Lenalidomide (Revlimid®)in Patients With Non-Deletion(5q) Low to...” NCT01062152 ↗3“Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)” NCT00700206 ↗ “Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug” PMID 19439093 ↗ May 2009 “Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets)” NCT00701870 ↗ |
| Action | Inhibit | “a glutathione S-transferase P1-1 inhibitor” PMID 19439093 ↗ May 20091“Glutathione S-transferase Pi inhibitor” CHEMBL2110585 ↗ |
| Modality | Small molecule | — CHEMBL2110585 ↗ |
| Route | Intravenous | “intravenously (IV) on days 1 to 5 of a 14-day cycle” PMID 19439093 ↗ May 2009 |
| Target | GSTP1 | “Glutathione S-transferase Pi inhibitor” CHEMBL2110585 ↗ |